Cargando…

Doxorubicin Loaded Magnesium Oxide Nanoflakes as pH Dependent Carriers for Simultaneous Treatment of Cancer and Hypomagnesemia

Doxorubicin (DOX) is an anticancer drug commonly used in treating cancer; however, it has severe cytotoxicity effects. To overcome both the adverse effects of the drug and mineral deficiency (i.e., hypomagnesemia) experienced by cancer patients, we have developed magnesium oxide (MgO) nanoflakes as...

Descripción completa

Detalles Bibliográficos
Autores principales: Ranathunge, Tharindu A., Karunaratne, D.G.G.P., Rajapakse, R.M.G., Watkins, Davita L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409820/
https://www.ncbi.nlm.nih.gov/pubmed/30736270
http://dx.doi.org/10.3390/nano9020208
_version_ 1783402076199452672
author Ranathunge, Tharindu A.
Karunaratne, D.G.G.P.
Rajapakse, R.M.G.
Watkins, Davita L.
author_facet Ranathunge, Tharindu A.
Karunaratne, D.G.G.P.
Rajapakse, R.M.G.
Watkins, Davita L.
author_sort Ranathunge, Tharindu A.
collection PubMed
description Doxorubicin (DOX) is an anticancer drug commonly used in treating cancer; however, it has severe cytotoxicity effects. To overcome both the adverse effects of the drug and mineral deficiency (i.e., hypomagnesemia) experienced by cancer patients, we have developed magnesium oxide (MgO) nanoflakes as drug carriers and loaded them with DOX for use as a targeted drug delivery (TDD) system for potential application in cancer therapy. The synthesis employed herein affords pure, highly porous MgO nanoparticles that are void of the potentially harmful metal contaminants often discussed in the literature. Purposed for dual therapy, the nanoparticles exhibit an impressive 90% drug loading capacity with pH dependent drug releasing rates of 10% at pH 7.2, 50.5% at pH 5.0, and 90.2% at pH 3. Results indicate that therapy is achievable via slow diffusion where MgO nanoflakes degrade (i.e., dissolve) under acidic conditions releasing the drug and magnesium ions to the cancerous region. The TDD system therefore minimizes cytotoxicity to healthy cells while supplying magnesium ions to overcome hypomagnesemia.
format Online
Article
Text
id pubmed-6409820
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64098202019-03-11 Doxorubicin Loaded Magnesium Oxide Nanoflakes as pH Dependent Carriers for Simultaneous Treatment of Cancer and Hypomagnesemia Ranathunge, Tharindu A. Karunaratne, D.G.G.P. Rajapakse, R.M.G. Watkins, Davita L. Nanomaterials (Basel) Article Doxorubicin (DOX) is an anticancer drug commonly used in treating cancer; however, it has severe cytotoxicity effects. To overcome both the adverse effects of the drug and mineral deficiency (i.e., hypomagnesemia) experienced by cancer patients, we have developed magnesium oxide (MgO) nanoflakes as drug carriers and loaded them with DOX for use as a targeted drug delivery (TDD) system for potential application in cancer therapy. The synthesis employed herein affords pure, highly porous MgO nanoparticles that are void of the potentially harmful metal contaminants often discussed in the literature. Purposed for dual therapy, the nanoparticles exhibit an impressive 90% drug loading capacity with pH dependent drug releasing rates of 10% at pH 7.2, 50.5% at pH 5.0, and 90.2% at pH 3. Results indicate that therapy is achievable via slow diffusion where MgO nanoflakes degrade (i.e., dissolve) under acidic conditions releasing the drug and magnesium ions to the cancerous region. The TDD system therefore minimizes cytotoxicity to healthy cells while supplying magnesium ions to overcome hypomagnesemia. MDPI 2019-02-06 /pmc/articles/PMC6409820/ /pubmed/30736270 http://dx.doi.org/10.3390/nano9020208 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ranathunge, Tharindu A.
Karunaratne, D.G.G.P.
Rajapakse, R.M.G.
Watkins, Davita L.
Doxorubicin Loaded Magnesium Oxide Nanoflakes as pH Dependent Carriers for Simultaneous Treatment of Cancer and Hypomagnesemia
title Doxorubicin Loaded Magnesium Oxide Nanoflakes as pH Dependent Carriers for Simultaneous Treatment of Cancer and Hypomagnesemia
title_full Doxorubicin Loaded Magnesium Oxide Nanoflakes as pH Dependent Carriers for Simultaneous Treatment of Cancer and Hypomagnesemia
title_fullStr Doxorubicin Loaded Magnesium Oxide Nanoflakes as pH Dependent Carriers for Simultaneous Treatment of Cancer and Hypomagnesemia
title_full_unstemmed Doxorubicin Loaded Magnesium Oxide Nanoflakes as pH Dependent Carriers for Simultaneous Treatment of Cancer and Hypomagnesemia
title_short Doxorubicin Loaded Magnesium Oxide Nanoflakes as pH Dependent Carriers for Simultaneous Treatment of Cancer and Hypomagnesemia
title_sort doxorubicin loaded magnesium oxide nanoflakes as ph dependent carriers for simultaneous treatment of cancer and hypomagnesemia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409820/
https://www.ncbi.nlm.nih.gov/pubmed/30736270
http://dx.doi.org/10.3390/nano9020208
work_keys_str_mv AT ranathungetharindua doxorubicinloadedmagnesiumoxidenanoflakesasphdependentcarriersforsimultaneoustreatmentofcancerandhypomagnesemia
AT karunaratnedggp doxorubicinloadedmagnesiumoxidenanoflakesasphdependentcarriersforsimultaneoustreatmentofcancerandhypomagnesemia
AT rajapaksermg doxorubicinloadedmagnesiumoxidenanoflakesasphdependentcarriersforsimultaneoustreatmentofcancerandhypomagnesemia
AT watkinsdavital doxorubicinloadedmagnesiumoxidenanoflakesasphdependentcarriersforsimultaneoustreatmentofcancerandhypomagnesemia